Research Methods
We use the latest discovery methods in computational drug design and bioinformatics combined with predictive in vitro assays to determine most relevant bio-molecular targets and their fitting small-molecule inhibitor or agonist candidates. These tools have been essential in making right choices within huge amount of data generated by the molecular sciences, and to turn this the data into insightful guidelines for novel therapeutic compounds. Their eventual destiny is to turn into active principles of our forthcoming products.
Phases of Development
Target Identification
Determination of relevant molecular target (protein or oligonucleotide) or active compound having known interaction with target of choice. Verification of activity or target “druggability” via computational modeling, appropriate cell assays, next generation sequencing and proteomics.
Compound Selection
Selection of most promising natural compounds interacting with target of choice using in silico screening such as computational docking accompanied by cell assays.
Lead Validation
Examination of key bio-molecular interactions between lead compounds and target employing X-ray crystallography and computational drug design strategies such as docking and binding free energy calculations.
Lead Optimization
Enhancement of compound properties such as permeability, selectivity or resistance to metabolic transformations. This stage embraces extensive use of computational design coupled with organic synthesis and cell assays.
In Vivo Assessments
Verification of compound potency, selectivity, possible toxicity, pharmacokinetic and pharmacodynamic properties in animal models.
Product Formulation
Adoption of specific pharmaceutical excipients and active compound delivery systems to achieve best product performance.
Compound Production
Use of biotechnological methods such as enzyme, plant or microorganism enhancements to secure cost-effective production of potent ingredients.
